Silence Therapeutics plc (OTCMKTS:SLNCF – Get Free Report) shares were down 7.2% during trading on Tuesday . The company traded as low as $6.22 and last traded at $6.22. Approximately 404 shares traded hands during mid-day trading, a decline of 76% from the average daily volume of 1,696 shares. The stock had previously closed at $6.70.
Silence Therapeutics Trading Down 7.2 %
The company has a 50 day moving average of $6.54 and a two-hundred day moving average of $7.20.
Silence Therapeutics Company Profile
Silence Therapeutics plc, a biotechnology company, focuses on the discovery and development novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases. The company's mRNAi GalNAc Oligonucleotide Discovery platform consists of precision engineered product candidates designed to target specific disease-associated genes in the liver.
Further Reading
- Five stocks we like better than Silence Therapeutics
- Using the MarketBeat Dividend Yield Calculator
- Biohaven Stock Soars on Drug Trial Results: Time to Jump In?
- Where Do I Find 52-Week Highs and Lows?
- Is AMD a Legitimate Threat to NVIDIA? What Investors Should Watch
- The How And Why of Investing in Oil Stocks
- Novo Nordisk’s Setback Won’t Last: A Game-Changing Drug Emerges
Receive News & Ratings for Silence Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Silence Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
